Effect of Two Cognitive-Behavioral Interventions on Cervical Cancer Patients
Launched by NATIONAL INSTITUTE OF CANCEROLOGÍA · Nov 13, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Cervical cancer is the fourth cause of morbidity and mortality worldwide, being one of the most important threats to women's health. More than 83,000 women were diagnosed with cervical cancer and 36,000 died in the Region of the Americas in 2012. This phenomenon will increase by 45% for 2030.
During the natural history of Cervical cancer, and as a consequence of therapeutic approaches, a certain proportion of the patients may have emotional reactions leading to psychological disorders, as severe as those disease complications, which also deteriorate their quality of life. The most frequent...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- * PATIENTS:
- • Affiliated to the MICAELA (Modelo Integral para el Cáncer Cervicouterino Localmente Avanzado y Avanzado) program
- • Ability to understand the study and to provide signed informed consent
- • Diagnosed with locally advanced and advanced cervical cancer
- • Patients newly diagnosed or with recurrence about to start treatment
- • Patients with moderate or severe anxiety, and/or depression symptoms or maladaptive coping
- * PRIMARY CAREGIVERS:
- • Relatives, acquaintance or friends reported to be the principal caregiver of the patient
- • Relatives, acquaintance or friends who do not perceived economic remuneration for taking care of the patient
- Exclusion Criteria:
- * PATIENTS:
- • Patients with psychological or psychiatric treatment or who received previous mental-health treatment.
- • Patients with any alteration of the Central Nervous System
- • Patients with moderated or severe cognitive impairment
- • Patients under palliative care or in terminal phase
- • PRIMARY CAREGIVERS
- • Caregivers with severe hearing and/or visual problems
- • Caregivers with a professional or technical training in patient care
- • Elimination criteria Patients referred to palliative care
About National Institute Of Cancerología
The National Institute of Cancerología (INCan) is a premier research and healthcare institution dedicated to the prevention, diagnosis, and treatment of cancer in Mexico. As a leading sponsor of clinical trials, INCan focuses on advancing oncology research through innovative methodologies and rigorous scientific protocols. With a commitment to improving patient outcomes, the institute collaborates with national and international partners to conduct studies that address critical challenges in cancer care. INCan strives to enhance the understanding of cancer biology and therapeutic strategies, ultimately contributing to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mexico City, Tlalpan, Mexico
Patients applied
Trial Officials
Jessica Salazar, MSc
Study Chair
National Cancer Institute from Mexico
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials